Paclitaxel (1), originally isolated from the Pacific yew tree Taxus brevofolia, 1 has attracted much attention as a target for chemical and medicinal research 2,3 due to its structural complexity and biological activity. 4 It has been shown to have strong antitumor activity against a variety of malignancies including ovarian, breast, and lung cancers. 5 The structure-activity relationship (SAR) studies have demonstrated that the side chain at the C-13 position of A-ring in paciltaxel is essential for the anticancer activity. 6 A number of analogues with modifications at the side chain have been synthesized and evaluated for the biological activity.
7 A representative example is docetaxel 2 with a N-t-Boc moiety 
Notes
replacing the N-benzoyl group at the 3'-position of the 13-side chain. 8 The t-Boc analogue has been shown to have some increased potency in cytotoxicity or tubulin polymerization assays.
9 As an extension of our continuing efforts in paclitaxel chemistry, 10 we became interested in paclitaxel analogues with new structural modifications at the 13-side chain: particularly, the one (3) with no nitrogen at the 3'-position. We herein report the results from the studies on its synthesis and biological evaluation.
The synthesis of 3 started from trans-3,4-diphenyl-2-isoxazoline-5-methanol (4) which had been prepared in three steps from benzaldehyde according to the literature procedure. 11 The racemic isoxazoline derivative was first oxidized using RuCl 3 and NaIO 4 in the 2 : 2 : 3 mixture of CCl 4 -CH 3 CN-Phosphate Buffer (pH 7.2) 12 to give trans-3,4-diphenyl-5-carboxy-2-isoxazoline (5) in good yield (85%). The isoxazoline carboxylic acid was then coupled using DCC/DMAP with 7-TES-baccatin III (6) 13 to afford 7 as a 6 : 4 diastereomeric mixture in 65% yield. The triethylsilyl group at C-7 of 7 was removed readily under the acidic conditions to yield 8 in 87% yield. The isoxazoline ring in the side chain of 7 was cleaved by catalytic hydrogenolysis (H 2 , B(OH) 3 , Raney-Ni, 7 : 1 MeOH-H 2 O) 14 to produce a mixture of two separable diastereomers in 72% yield (9a, major product, 47%; 9b, minor product, 25%). Finally, the diastereomers were separately desilylated with the treatment of HF/Py to obtain two diastereomers (3a and 3b) of the target molecule in 88% yield (Scheme 1). The absolute configurations of the stereocenters at the side chain of each diastereomer were not established.
The biological activities of deazapaclitaxel isomers (3a and 3b) and isoxazoline intermediate (8) were evaluated in in vitro cytotoxicity assays against several human tumor cell lines. The results are given in Table 1 . All of them exhibited no significant anticancer activities in all assays. The deaza analogs displayed very weak activities against a few cell lines and no activities against most cell lines. The isoxazoline molecule was virtually inactive against all the cell lines. These observations clearly indicate that 1) the amide functionality of the side chain is an essential structural element required for the anticancer activity; and 2) the major structural modification of the C-13 side chain such as the incorporation of a ring results in the complete loss of the anticancer activity.
Experimental Section
Preparation of compound 5. trans-3,4-Diphenyl-2-isoxazoline-5-methanol (4) (50 mg, 0.197 mmol) was dissolved in CCl 4 /CH 3 CN/phosphate buffer (pH 7.5) (0.35 mL/0.35 mL/0.5 mL, 2/2/3). To this solution at 0 o C was added RuCl 3 (2 mg, 0.00985 mmol), NaIO 4 (42 mg, 0.591 mmol). After stirring at room temperature for 12h, the reaction mixture was diluted with EtOAc (50 mL) and extracted with saturated NaHCO 3 (2 × 50 mL). To the aqueous solution was added 3 N HCl (120 mL) and the resulting mixture was extracted with EtOAc (3 × 50 mL). 4, 138.5, 130.5, 129.7, 129.0, 128.9, 128.4, 127.8, 126.3, 86.7, 58.5 ; HRMS m/z calcd for C 16 H 13 NO 3 + H 268.0974, obsd 268.0975.
Preparation of compound 7. To a toluene/THF (4 mL, 1/3, v/v) mixture of 7-TES-baccatin III 6 (100 mg, 0.14 mmol) and 5 (75 mg, 0.28 mmol) were added DCC (56 mg, 0.28 mmol) and DMAP (17 mg, 0.14 mmol). The reaction mixture was stirred at room temperature for 10 h and then subjected to silica gel chromatography (50% ethyl acetate in hexane) to afford 7 (96 mg, 65%): m.p. 86-88 5, 171.3, 170.7, 169.9, 167.8, 159.0, 140.9, 138.1, 134.5, 134.45, 134.4, 130.8, 130.4, 130.3, 129.5, 129.4, 129.3, 129.2, 128.31, 128.26, 128.23, 87.2, 87.0, 85.0, 84.9, 81.6, 81.4, 79.7, 79.5, 78.9, 77.9, 77.5, 75.8, 75.7, 75.6, 72.9, 72.3, 59.3, 59.2, 58.2, 47.6, 43.9, 37.9 35.8, 27.3, 23.2, 22.6, 21.8, 21.6, 21.5, 15.3, 15.1, 10.77, 10.72, 7.4, 6. 4, 204.3 171.9, 171.2, 170.9, 170.8, 167.7, 159.03, 143.2, 138.0, 137.9, 134.4, 133.7, 131.2, 130.8, 130.4, 130.3, 130.0, 129.9, 129.5, 129.4, 129.3, 129.2, 129.1, 128.25, 128.2, 87.2, 86.98, 85.2, 85.13, 81.5, 81.4, 80.2, 79.9, 78.7, 77.91, 77.50, 76.2, 75.9, 75.7, 72.8, 72.3, 59.3, 59.2, 59.1, 58.4, 46.4, 43.9, 36.4, 36.2, 32.3, 30.4, 27.5, 23.3, 23.1, 22.6, 21.5, 15.8, 15.7, 10.3 ; HRMS m/z calcd for C 47 H 50 O 13 N + H 836.3282, obsd 836.3285.
Preparation of compounds 9a and 9b. To a MeOH-H 2 O (2 mL, 7/1, v/v) solution of 7 (50 mg, 0.0526 mmol) were added Raney-Ni (10 mol%) and B(OH) 3 (13 mg, 0.21 mmol). Under the pressure of H 2 gas (1 atm, balloon), the reaction mixture was stirred at 0 o C for 8h. The reaction mixture was then diluted with EtOAc (50 mL), filtered to remove Raney-Ni, and washed with 1 N HCl (50 mL) and brine (50 mL). The organic layer was dried and concentrated in vacuo. The residue was chromatographed (1 : 1 ethyl acetatehexane) to give the desired products 9a (23 mg, 47%) and 9b (13 mg, 25%). 6, 200.8, 173.6, 170.9, 169.8, 167.7, 141.3, 136.2, 135.6, 134.44, 134.36, 134.1, 130.7, 130.0, 129.9, 129.8, 129.3, 129.2, 128.8, 84.9, 81.4, 79.7, 77.1, 75.6, 75.4, 72.9, 71.7, 59.1, 57.5, 47.5, 43.8, 37.9, 35.9, 27.2, 22.9, 21.6, 21.5, 15.2 10.7, 7.4, 5.95 07 (d. J = 7.32 Hz, 2H), 7.94 (d, J = 7.44 Hz, 2H), 1H), 3H), 7H), 6.31 (s, 1H), 6.03 (m, 1H), 5.64 (d, J = 6.93 Hz, 1H), 5.17 (d, J = 6.45 Hz, 1H), 4.96 (d, J = 8.31 Hz, 1H), 4.79 (m, 1H), 4.69 (s, OH), 4.38 (m, 1H), 4.29 (d, J = 8.37 Hz, 1H), 4.15 (d, J = 8.28 Hz, 1H), 3.83 (d, J = 7.47, 1H), 3.74 (d, J = 6.90, OH) , 2.55 (m, 1H), 2.43 (s, 3H), 2.31 (m, 2H), 2.14 (s, 3H), 1.88 (m, 1H), 1.67 (s, 3H), 1.43 (s, 3H), 1.18 (s, 3H), 1.11 (s, 3H), 0.91 (m, 9H) , 0.57 (m, 6H); 13 C NMR (300 MHz, CDCl 3 , ppm) 202. 4, 200.0, 172.5, 170.7, 169.8, 167.7, 140.5, 136.3, 134.9, 134.4, 134.3, 130.7, 130.1, 129.9, 129.7, 129.3, 129.2, 129.0, 84.8, 81.7, 79.4, 77.9, 75.7, 75.4, 73.0, 71.8, 59.2, 57,4, 47.6, 43.7, 37.9, 36.3, 27.2, 23.4, 21.5, 21.3, 14.6 10.6, 7.4, 5.9 .
Preparation of compounds 3a and 3b. To a pyridine solution (1 mL) of 9a or 9b (20 mg, 0.021 mmol) was added HF-Pyridine (50 µL) at 0 o C. After stirring at room temperature for 4 h, the reaction mixture was diluted with EtOAc (100 mL) and washed first with a saturated solution of CuSO 4 (2 × 50 mL) and then brine (50 mL). The organic layer was dried and concentrated in vacuo. The residue was chromatographed (1 : 1 ethyl acetatehexane) to give desired product (15.5 mg, 0.018 mmol, 88% 5, 200.8, 173.6, 171.9, 171.0, 167.7, 141.6, 136.2, 135.5, 134.52, 134.48, 133.3, 130.8, 130.0, 129.9, 129.8, 129.4, 129.3, 128.9, 85.1, 81.4, 80.0, 77.9, 77.0, 76.3, 75.7, 75.5, 72.8, 71.7, 59.2, 57.6, 46.3, 43.7, 36.2, 36.1, 30.4, 27.4, 22.9, 22.5, 21.5, 15.8 4, 200.0, 172.5, 171.9, 170.8, 167.7, 142.8, 136.2, 134.9, 134.5, 134.48, 134.0, 130.7, 130.2, 129.8, 129.7, 129.4, 129.1, 85.1, 81.7, 79.8, 77.9, 77.1, 76.3, 75.5, 75.1, 72.9, 71.9, 59.3, 57,6, 46.4, 43.7, 36.6, 36.3, 27.4, 23.4, 22.2, 21.5, 15 
